Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ICHD (ICHD-III).
At least 8 days of migraine per month.
Adequate compliance with study procedures.
Availability of a migraine diary for at least one month prior to enrollment.
Ongoing attack before administration.
Included in the TACHIS study (NCT06409845)
You may not be if
Subjects with contraindications to the use of eptinezumab.
Concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes.
Pregnancy and breastfeeding.
Changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.
